Doximity Stock Is Falling After Hours: What’s Going On?

Doximity Inc (NYSE: DOCS) shares are trading lower in Tuesday's after-hours session on the heels of the company's fourth-quarter report. Soft guidance appears to be driving shares lower. 

Doximity Inc (NYSE:DOCS) shares are trading lower in Tuesday’s after-hours session on the heels of the company’s fourth-quarter report. Soft guidance appears to be driving shares lower. 

What Happened: Doximity said fourth-quarter revenue increased 18% year-over-year to $110.97 million, which narrowly beat consensus estimates of $110.09 million, per Benzinga Pro. The company reported adjusted earnings of 20 cents per share, which beat estimates of 17 cents per share. 

Doximity generated operating cash flow of $46.6 million, down 1% year-over-year. Free cash flow was up 2% year-over-year to $45.6 million. 

“With the public health emergency officially over, we’re proud to emerge with a record number of providers using our physician cloud in Q4 to power their scheduling, fax, e-signature, and telehealth needs,” said Jeff Tangney, co-founder and CEO of Doximity.

Doximity said it expects first-quarter revenue to be between $106.5 million and $107.5 million versus estimates of $112.09 million. Full-year revenue is expected to be between $500 million and $506 million versus estimates of $507.05 million.

Doximity will host a conference call at 5 p.m. ET to discuss these results.

Doximity also announced an integration with MEDITECH, which will allow medical professionals to launch a Doximity Dialer voice or video telehealth visit directly from MEDITECH’s app, Expanse Now.

See Also: Best Healthcare Penny Stocks

DOCS Price Action: Doximity shares were down 6.97% after hours at $31.50 at time of publication, according to Benzinga Pro.

Photo: courtesy of Doximity.

Total
0
Shares
Related Posts
Read More

Canadian Company Lifeist Says Farewell To Cannabis Business Unit, Turns To Nutraceuticals

Canadian wellness company Lifeist has agreed to sell its CannMart cannabis subsidiaries to 1463663 B.C. for $3.72m. The deal, which is expected to improve cash flow and operational costs, will see all shares of the CannMart Group transferred to the buyer. The consideration of $5m plus adjusted inventory will be paid to Lifeist as follows: $500,000 cash will be paid upon the transaction's completion, with a further $4.5m in a senior secured vendor takeback loan paid through monthly repayments. Additionally, Lifeist will receive equity warrants to acquire 9.9% of Tierra Corp's equity, as parent company of 1463663 B.C. Once the deal is finalised, Lifeist will be freed to operate in the nutraceutical sector, with North America's $88.3bn predicted to grow to $118.7bn by 2028, according to the company.

LFST

Read More

Acrivon Therapeutics Presents Data Demonstrating Capabilities Of Its AP3 Platform And ACR-368 OncoSignature Assay For Patient Responder Identification At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Data presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the ACR-368-tailored, proteomics-based OncoSignature assay for the prediction

ACRV